{"id":4015,"date":"2018-11-19T18:14:51","date_gmt":"2018-11-19T17:14:51","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2018\/10\/26102018_Galecto-Biotech-Raises-1.pdf"},"modified":"2018-11-19T18:14:51","modified_gmt":"2018-11-19T17:14:51","slug":"26102018_galecto-biotech-raises-3","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/galecto-biotech-raises-e79-million-in-series-c-financing-co-led-by-ysios-capital-and-orbimed-to-advance-galectin-inhibitor-to-late-stage-clinical-development\/26102018_galecto-biotech-raises-3\/","title":{"rendered":"26102018_Galecto Biotech Raises"},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-4015","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"\n